收藏切换
Recent advances in the use of proton pump inhibitors in metabolic diseases
收藏切换
Yu-qing WANG1, Guo-cheng WANG1, *, Bao-lian WANG2
Acta Pharmaceutica Sinica | 2026, 61(2) : 349 - 355
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(2): 349-355
• Reviews •
Recent advances in the use of proton pump inhibitors in metabolic diseases
Full
Yu-qing WANG1, Guo-cheng WANG1, *, Bao-lian WANG2
Affiliations
  • 1School of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
  • 2Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Published: 2026-02-12 doi: 10.16438/j.0513-4870.2025-0549
Outline
收藏切换

As first-line drugs for inhibiting gastric acid and treating digestive system diseases, proton pump inhibitors (PPI) have been found in recent studies to have multi-pathway effects on the regulation of metabolic diseases. There are both therapeutic potentials and risks in the prevention and treatment of metabolic diseases. Studies have indicated that PPI participate in the pathophysiological processes of obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD) through multiple regulatory mechanisms, including reducing levels of appetite-related hormones, improving insulin sensitivity, decreasing hepatic fat accumulation, and modulating fibrotic progression. However, long-term use of PPI has potential risks, including electrolyte disorders, intestinal flora imbalance, osteoporosis, increased risk of fractures, and increased risk of cardiovascular diseases. In clinical application, the medication regimen should be precisely formulated based on the individual characteristics of patients, long-term use without indications should be avoided, and relevant risks should be closely monitored.

proton pump inhibitor  /  metabolic disease  /  obesity  /  type 2 diabetes mellitus  /  non-alcoholic fatty liver disease  /  application and risk
王雨晴, 王国成, 王宝莲. 质子泵抑制剂在代谢性疾病中的最新应用进展. 药学学报, 2026 , 61 (2) : 349 -355 . DOI: 10.16438/j.0513-4870.2025-0549
Yu-qing WANG, Guo-cheng WANG, Bao-lian WANG. Recent advances in the use of proton pump inhibitors in metabolic diseases[J]. Acta Pharmaceutica Sinica, 2026 , 61 (2) : 349 -355 . DOI: 10.16438/j.0513-4870.2025-0549
Year 2026 volume 61 Issue 2
505
250
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-0549
  • Receive Date:2025-04-22
  • Online Date:2026-09-21
  • Published:2026-02-12
Article Data
Affiliations
History
  • Received:2025-04-22
  • Revised:2025-07-30
Affiliations
    1School of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
    2Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-0549
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT